Delving into the Latest Updates on Polidocanol with Synapse

This randomized, double-blind, parallel clinical trial will compare the clinical and aesthetic outcomes of polidocanol foam sclerotherapy alone versus polidocanol foam associated with long-pulse 1064 nm Nd:YAG transdermal laser in the treatment of lower limb tributary varicose veins. The primary endpoint is venous occlusion rate at 30 days assessed by Doppler ultrasound. Secondary outcomes include cutaneous hyperpigmentation, pain, patient satisfaction, and adverse events.

Start Date01 Jan 2026

Sponsor / Collaborator-

ChiCTR2500115124

/ Not yet recruitingNot ApplicableIIT

Study on Polidocanol Sclerotherapy for Pyogenic Granuloma

Start Date01 Jan 2026

Sponsor / Collaborator-

CTRI/2025/07/091873

/ Not yet recruitingPhase 4IIT

RANDOMISED CONTROL TRAIL COMPARING EFFICACY OF POLIDOCANOL FOAM SCLEROTHERAPY AND RUBBER BAND LIGATION FOR THE TREATMENT OF GRADE 1 GRADE 2 AND EARLY GRADE 3 INTERNAL HEMORRHOIDS - NIL

Start Date10 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Polidocanol

Login to view more data

100 Translational Medicine associated with Polidocanol

Login to view more data

100 Patents (Medical) associated with Polidocanol

Login to view more data

1,183

Literatures (Medical) associated with Polidocanol

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Polidocanol augments high-intensity focused ultrasound efficacy for hyperintense fibroids on T2WI: a retrospective cohort study

Review

Author: He, Hong-ni ; He, Tian-wen ; Tang, Ying ; Lin, Chuan ; Tian, Ling ; Hu, Hui-quan ; Li, Jun ; Xia, Yu ; Yang, Ming-tao

OBJECTIVE:

To compare the immediate efficacy and safety of high-intensity focused ultrasound (HIFU) monotherapy with the combination of ultrasound-guided intratumoral polidocanol injection and HIFU for the treatment of uterine fibroids with high T2-weighted imaging (T2WI) signal intensity.

METHODS:

In this retrospective study, 116 patients with T2-hyperintense uterine fibroids treated between January 2024 and May 2025 were enrolled. Patients were allocated to either HIFU monotherapy (the H group, n = 63) or combined polidocanol and HIFU therapy (the H + P group, n = 53). Thereafter, therapeutic parameters, the non-perfused volume ratio (NPVR), and adverse events were compared between the two groups after propensity score matching.

RESULTS:

The matched cohort comprised 53 patients per group. The median NPVR was significantly higher in the H + P group than in the H group (92.57% vs. 77.81%, p < 0.001). Additionally, a significantly greater proportion of patients in the H + P group achieved an NPVR ≥ 80% (87% vs. 43%, p < 0.001) and an NPVR ≥ 90% (60% vs. 9%, p < 0.001). The H + P group also required significantly less sonication time and lower total energy delivery (both p < 0.05). Furthermore, the overall incidence of adverse events was similar between the two groups (73.6% vs. 69.8%, p = 0.506). However, the H + P group exhibited a markedly lower incidence of sacrococcygeal pain (5.7% vs. 45.3%, p < 0.001).

CONCLUSION:

Pretreatment with ultrasound-guided intratumoral polidocanol injection may improve the immediate ablation efficacy of HIFU in T2-hyperintense uterine fibroids, reducing energy requirements and mitigating procedure-related sacrococcygeal pain. These findings highlight the potential of this combined therapy and underscore the need for prospective studies to confirm its long-term clinical benefits.

01 Mar 2026·Journal of Stomatology Oral and Maxillofacial Surgery

The use of fluoroscopy-guided sclerotherapy with foam polidocanol for retromolar trigon venous malformation: A case report and review of the literature

Article

Author: Baabdullah, Razan

Venous malformations (VMs) are vascular anomalies that can pose significant challenges in pediatric patients. This case report describes the successful treatment of a retromolar trigone VM in an eight-year-old child using a single injection of 3 % polidocanol foam using the Tessari technique and administered under fluoroscopic guidance. This resulted in significant reduction of the lesion and complete resolution of symptoms without complications. Follow-up evaluations were scheduled at two weeks, one month, three months, six months, and twelve months post-procedure. At six months post-procedure, there was no detectable lesion, though a minimal residual bluish discoloration persisted on the lingual surface. At twelve months, this discoloration remained unchanged, with no signs of recurrence. This case highlights the efficacy and safety of polidocanol foam sclerotherapy as a minimally invasive treatment option for pediatric maxillofacial VMs. Further studies are warranted to evaluate the long-term outcomes and broader applicability of this technique.

01 Feb 2026·ANNALS OF VASCULAR SURGERY

Sclerotherapy With Polidocanol for Head and Neck Vascular Anomalies: A Single-Center Experience

Article

Author: Ayyildiz, Hakan ; Ersoy, Berke ; Barburoglu, Mehmet

BACKGROUND:

To evaluate the efficacy and safety of percutaneous sclerotherapy with polidocanol in head and neck vascular anomalies, including hemangiomas, venous malformations, and venolymphatic malformations.

METHODS:

This retrospective study included 14 patients (6 females, 8 males; median age 25.5 years, range 2-60) treated between August 2020 and November 2022. Lesion types were confirmed by magnetic resonance imaging (MRI) and ultrasound, and all underwent percutaneous sclerotherapy with polidocanol under ultrasound and fluoroscopic guidance. Outcomes were assessed using pre- and post-treatment MRI volumetry, clinical evaluation, and complication monitoring.

RESULTS:

A total of 27 sclerotherapy sessions were performed. The mean pre-treatment lesion volume was 11.19 ± 10.32 cm³, decreased to 4.89 ± 2.97 cm³ post-treatment, corresponding to a mean reduction of 56.3% (P < 0.001). Clinically, 35.7% of patients demonstrated excellent outcomes, while 64.3% showed moderate improvement. Hemangiomas responded especially well, often requiring fewer sessions. The most common adverse events that occurred were transient swelling (92.9%) and pain (85.7%), both of which resolved spontaneously. Minor adverse events were transient swelling (92.9%) and pain (85.7%), which resolved spontaneously. One patient developed localized necrosis that healed without sequelae. No systemic or severe complications occurred.

CONCLUSION:

Polidocanol sclerotherapy is a safe and effective treatment option for low-flow vascular malformations of the head and neck, with substantial lesion volume reduction and minimal complications. Its efficacy in hemangiomas highlights a promising therapeutic avenue where limited prior evidence exists. Given its favorable safety profile compared to ethanol and other sclerosants, polidocanol should be considered particularly suitable for cosmetically and functionally sensitive head and neck lesions.

10

News (Medical) associated with Polidocanol

28 Jan 2026

·www.globenewswire.com

Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea

Jan. 26, 2026 -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic therapies, today announced the execution of a licensing agreement for 10XB-101, its investigational product for focal fat reduction and body contouring, along with a strategic equity investment by BNC Korea (KOSDAQ:256840), a leading healthcare and aesthetics-focused company in South Korea. “We are delighted to enter this strategic partnership with BNC Korea for 10XB-101, marking a significant milestone for Leios Therapeutics,” said Ted White, Chief Executive Officer of Leios Therapeutics. “BNC Korea’s leadership in the aesthetics market, deep regional expertise, and outstanding commercialization capabilities make them an ideal partner to help bring 10XB-101 to market. The strategic investment further validates the potential of our pipeline, strengthens our balance sheet and supports the advancement of our clinical development program and long-term growth strategy.” Choi Wan-gyo, CEO of BNC Korea added, “We are pleased to partner with Leios Therapeutics on 10XB-101, a promising candidate in the rapidly expanding body contouring market, which demonstrated compelling results in the Phase 2b study, with 64% and 70%% of completers in higher dose groups (3.0% and 4.5%) achieving grade 2 or greater improvement in both clinician and patient submental fat scales (CSFS and PSFS) compared to 0% on placebo, as part of the patient reported outcome assessment. Importantly, a pristine safety profile of 10XB-101 was observed. We believe this product has the potential to address unmet needs in focal fat treatment, and we look forward to working closely with the Leios team to advance development and commercialization in our region.” Under the terms of the agreement, Leios Therapeutics has granted BNC Korea the rights to develop and commercialize 10XB-101 in the following territories; South Korea, Taiwan, Singapore, Indonesia, Thailand, Vietnam, Russia, Belarus, and Kazakhstan. Vault Advisors acted as the exclusive financial advisor to Leios Therapeutics in the transaction. 10XB-101 is being developed as a best-in-class minimally invasive injectable treatment designed to reduce focal fat deposits and enhance body contouring outcomes. Leios has completed Phase 2 trials in submental fat reduction indication. Leios Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for aesthetic indications. The company’s mission is to deliver scientifically differentiated products that offer meaningful benefits to patients, healthcare providers and partners. BNC Korea (KOSDAQ: 256840), founded in 2007 and based in Daegu, South Korea, is a manufacturer of dermal fillers, specializing in wrinkle improvement fillers and adhesion prevention products. The company researches and develops strategic application products that will lead the next-generation bio markets for medical devices, pharmaceuticals and cosmeceutical products containing physiologically active substances by processing biomaterials such as hyaluronic acid and collagen. The content above comes from the network. if any infringement, please contact us to modify.

License out/inClinical Result

02 Jan 2026

·www.prnewswire.com

United Vein & Vascular Centers Expands Dallas-Area Presence With Opening of Rockwall Clinic

ROCKWALL, Texas, Jan. 2, 2026 /PRNewswire/ -- United Vein & Vascular Centers (UVVC), a national leader in minimally invasive vein and vascular care, is proud to announce the official opening of its newest clinic in Rockwall, Texas, expanding access to expert outpatient care across the northeast Dallas area. Beginning today, patients can visit the new facility located at 1005 W Ralph Hall Parkway, Suite 221, Rockwall, TX 75032, for advanced, personalized treatment of vein and vascular conditions. The Rockwall clinic broadens UVVC's growing national network of state-of-the-art centers, providing residents of Rockwall County and surrounding communities with convenient access to comprehensive vein care close to home. At the Rockwall location, patients can expect compassionate, results-driven care delivered through minimally invasive procedures designed to relieve leg pain, improve circulation, and restore comfort and mobility. UVVC's team develops individualized treatment plans using advanced imaging and technology to achieve long-term relief and superior outcomes. Patients at the Rockwall clinic will have access to a full suite of modern procedures, including: Radiofrequency Ablation (RFA): Heat-based treatment that closes damaged veins to relieve discomfort. VenaSeal™ Closure System: Non-thermal adhesive procedure that seals diseased veins quickly and comfortably. Varithena®: Microfoam therapy that collapses problem veins and restores healthy blood flow. Microphlebectomy: Minimally invasive removal of large varicose veins through small incisions. Sclerotherapy: An injectable treatment that collapses affected veins and reroutes blood flow to healthier vessels. With the opening of the Rockwall clinic, United Vein & Vascular Centers now operates 15 clinics across Texas, expanding its reach and reaffirming its commitment to providing high-quality vein and vascular care throughout the state. For more information or to schedule a consultation at the Rockwall clinic, visit our website or call (800) 952-5954. About United Vein & Vascular Centers United Vein & Vascular Centers provides safe, effective outpatient care for vein and vascular disease at over 50 locations nationwide, including Florida, Georgia, Illinois, Colorado, Arizona and Texas. With state-of-the-art medical technology and board-certified physicians, UVVC remains at the forefront of vein and vascular healthcare. Media contact: Barbara Kramer or Mike Patino [email protected] SOURCE United Vein & Vascular Centers 21% more press release views with Request a Demo

03 Nov 2025

·www.prnewswire.com

United Vein & Vascular Centers Expands Atlanta Presence with Opening of Newnan Clinic

NEWNAN, Ga., Nov. 3, 2025 /PRNewswire/ -- United Vein & Vascular Centers (UVVC), a national leader in minimally invasive vein and vascular care, is proud to announce the official opening of its newest clinic in Newnan, Georgia. Beginning today, patients can visit the new facility located at 354 Newnan Crossing Bypass, Suite 210, Newnan, GA 30263, for expert, outpatient vein and vascular treatment. The Newnan clinic expands UVVC's growing network of state-of-the-art centers across the country, providing residents of Coweta County and the greater south metro Atlanta area with convenient access to expert vein and vascular care. Led by Dr. Conrad Manayan, D.O., a board-certified vein specialist, the Newnan clinic provides comprehensive care for a variety of vein and vascular conditions. Using advanced imaging and minimally invasive techniques, Dr. Manayan and his team create personalized treatment plans to relieve pain, improve circulation, and help patients regain comfort and mobility. Patients at the Newnan clinic will have access to a full suite of advanced, outpatient procedures, including: Radiofrequency Ablation (RFA): Heat-based treatment that closes damaged veins and alleviates leg discomfort. VenaSeal™ Closure System: A quick, non-thermal procedure that seals problem veins using a medical adhesive. Varithena®: Microfoam therapy that collapses diseased veins to restore healthy circulation. Microphlebectomy: Minimally invasive removal of large varicose veins through small incisions. Sclerotherapy: Injection treatment for spider veins and smaller varicose veins. The opening of the Newnan clinic reinforces UVVC's commitment to expanding access to expert vein care across Georgia and beyond. For more information or to schedule a consultation at the Newnan clinic, visit our website or call (800) 952-5954. About United Vein & Vascular Centers United Vein & Vascular Centers provides safe, effective outpatient care for vein and vascular disease at over 50 locations nationwide, including Florida, Georgia, Illinois, Colorado, Arizona and Texas. With state-of-the-art medical technology and board-certified physicians, UVVC remains at the forefront of vein and vascular healthcare. Media contact: Barbara Kramer or Mike Patino [email protected] SOURCE United Vein & Vascular Centers 21% more press release views with Request a Demo

100 Deals associated with Polidocanol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Polidocanol	C05BB02	DB06811

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
primary varicose veins	Japan	Kaigen Pharma Co., Ltd.	26 Jul 2006
Varicose Veins	Australia	Accelagen	27 Jul 2001
Bleeding esophageal varices	Japan	Kaigen Pharma Co., Ltd.	28 Jun 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Insufficiency	Phase 3	United States	Boston Scientific Corp.	01 Sep 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02557542 (OSVeC, CTgov)	Not Applicable	Varicose Veins	3	Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (One Stop Vein Clinic)	qzuznwontx(qfkjgugtvm) = vylqyewgvk txlbcjwqlc (mtoylthroy, lvrmxnftel - rdwpzqlvqg) View more	-	16 May 2025
				Endovenous laser ablation+Sodium Tetradecyl+Polidocanol (Normal Care Pathway)	qzuznwontx(qfkjgugtvm) = ydvttvwozo txlbcjwqlc (mtoylthroy, vizisqjeqn - bhdwousfys) View more
NCT05154955 (NEWS)	Phase 2	-	-	聚多卡醇-10XB101	uhwlsefrzy(erzxemwjfe) = bbavatgcqz ghjdhkbzri (qsogejlkje )	Positive	11 Mar 2024
				安慰剂	uhwlsefrzy(erzxemwjfe) = pdpdmdpihi ghjdhkbzri (qsogejlkje )
UEGW2022	Not Applicable	Hemorrhoids	46	Polidocanol foam sclerotherapy (SP)	cxiefddxzb(gmiifaawks) = ovghrllzmr ylirmsrssz (thtirkgzhg ) View more	Positive	09 Oct 2022
				Polidocanol foam (Hemorrhoidal artery ligation with recto-anal repair (HAL-RAR))	cxiefddxzb(gmiifaawks) = gvtymaapgx ylirmsrssz (thtirkgzhg ) View more
NCT03791775 (SCLEROFOAM, Pubmed \| Tech Coloproctol) Manual	Phase 2	Hemorrhoids	183	polidocanol foam	udszyizgdx(nptqlrrfpe) = yxavhpvgjy odcuuvpdyg (prccgceaxp ) View more	Positive	25 Mar 2022
NCT02462720 (COMFORT, CTgov)	Phase 4	Pain \| Varicose Veins	35	polidocanol (Varithena®)	mwvmapdvbe(zarpxfdhwg) = loltpweafn fidpmuranh (phphnpljbg, 2.90) View more	-	23 Jan 2018
				Varithena (Radiofrequency Ablation)	mwvmapdvbe(zarpxfdhwg) = vorlshzekv fidpmuranh (phphnpljbg, 2.90) View more
NCT02657252 (PG3T, CTgov)	Phase 4	Telangiectasis \| Varicose Veins	115	Glucose (Glucose)	vitxjhpiaw(lpvhjoowpn) = gwocdukxhq ukhudxquib (rzmjzasuds, 22.69) View more	-	28 Nov 2017
				Glucose (Polidocanol With Glucose)	vitxjhpiaw(lpvhjoowpn) = emlbepzcmo ukhudxquib (rzmjzasuds, 18.63) View more
NCT00758420 (Pubmed \| Phlebology)	Phase 2/3	Varicose Veins	77	Varithena 1%	zsbvbthkng(bhyfpvepsb) = reported as mild and generally resolved without sequelae tgocgvwrzo (stbhjkwpxt )	-	01 Apr 2017
				Placebo
NCT02054325 (CTgov)	Phase 4	Vein disorder \| Varicose Veins	106	Polidocanol with Glucose (Polidocanol With Glucose)	pcrtiqbozl(wxxjzfzumz) = yzpmkokjuj nxfzwdpjgk (yfneiixwnt, 9.09) View more	-	27 Jan 2017
				Glucose (Glucose)	pcrtiqbozl(wxxjzfzumz) = dnfxfxuiib nxfzwdpjgk (yfneiixwnt, 17.04) View more
NCT01072877 (VANISH-1, CTgov)	Phase 3	Varicose Veins	279	Placebo Vehicle (Vehicle)	numaqtuftj(fuzindridh) = siacuaujjw esfpmlaepz (sezltqwhuk, 0.452) View more	-	16 May 2014
				Polidocanol injectable foam (PEM) (Polidocanol Injectable Foam 0.125%)	numaqtuftj(fuzindridh) = ybingjjsaj esfpmlaepz (sezltqwhuk, 0.447) View more
NCT00928421 (CTgov)	Phase 2	Varicose Veins	16	Polidocanol	wvhpfphxii = srhezwgxov spipepxgky (bloqsmwisb, tsjuvlfpte - udanotrvpo) View more	-	02 Apr 2014